Using real world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies

PharmacoEconomics

21 March 2018 - This study examines whether real world data is incorporated in health technology assessment (HTA) of melanoma drugs by European HTA agencies, as well as differences in real world data use between agencies and across time.

HTA reports published between 1 January 2011 and 31 December 2016 were retrieved from websites of agencies representing five jurisdictions: England [NICE], Scotland [SMC], France [HAS], Germany [IQWiG] and The Netherlands [ZIN]. A standardised data extraction form was used to extract information on RWD inclusion for both REAs and CEAs.

Overall, 52 reports were retrieved, all of which contained REAs; CEAs were present in 25 of the reports. RWD was included in 28 of the 52 REAs (54%), mainly to estimate melanoma prevalence, and in 22 of the 25 (88%) CEAs, mainly to extrapolate long-term effectiveness and/or identify drug-related costs.

Read PharmacoEconomics article

Michael Wonder

Posted by:

Michael Wonder